News
News from us and our partners
News
Crossover
News
News
Industrial Biotech
News
Capital
News
Digital Medicine
News
Tags
Topics
0 results
- News
AAVantgarde Bio announces FDA Orphan Drug Designation for AAVB-081 for the treatment of Usher Syndrome type 1B Retinitis Pigmentosa
- News
Handbook for impact accountability in VC developed by coalition of impact-driven funds
- News
Women's Health Company Freya Biosciences Announces Key $10.4 Million Strategic Investment
- News
Cure51 Launches NHS-Approved Study With Cambridge University Hospitals and Seven Other Leading UK Oncology Institutions to Unlock Cancer Survival Secrets
- News
BrightHeart Secures FDA Clearance for First AI Software Revolutionizing Prenatal Fetal Heart Ultrasound Evaluations
- News
Elicit Plant announces €45 Million Investment Round to Accelerate Global Expansion
- News
TechBio startup Cure51 selects 10x Genomics Visium HD for new drug discovery initiative
- News
Noema Pharma announces first patients dosed in Phase 2b study with Gemlapodect (NOE-105), a first-in-class investigational therapy for Tourette Syndrome
- News
AAVantgarde Founder and CSO is elected as President of the European Society of Gene and Cell Therapy (ESGCT)
- News
deepc and The AI Centre for Value-Based Healthcare enter partnership to accelerate and transform NHS adoption of radiology AI
- News
Bioptimus and Proscia collaborate to accelerate AI innovation in scientific research and drug development for improved patient care
- News
Enhanced data security and quality via ISO 27001:2022 and SOC 2 certifications enables Moon Surgical to deliver actionable insights to healthcare providers
- News
Gradient Denervation Technologies appoints Stanton Rowe to Board of Directors and receives FDA approval to expand early feasibility study
- News
AAVantgarde appoints Ms. Lauren Kaskiel as Chief Business Officer
- News
Noema Pharma Announces NOE-105 (gemlapodect) Phase 2a Study in Tourette Syndrome met Primary and all Key Secondary Endpoints